IQVIA launches biotech division in Asia Pacific

Latest News

IQVIA has announced the Japan and Asia Pacific (JAPAC) expansion of IQVIA Biotech that delivers integrated clinical and commercial solutions for biotech and emerging biopharma companies.

The company said its IQVIA Biotech teams use lean operating procedures and scientific specialisation to deliver flexible solutions, powered by IQVIA’s technology-enabled services, that can help innovative companies reach their drug development and commercialisation milestones.

“Biotech companies are fueling rapid development of biologics, drugs, and vaccines, and when they succeed, we all succeed,” said Richard Staub, president, research and development solutions at IQVIA.

“By launching IQVIA Biotech in JAPAC, we can support the aspirations of biotech customers with agile solutions and resources dedicated to supporting smaller companies.”

IQVIA Biotech was launched in North America and Europe in early 2019. Since its launch, it has initiated hundreds of new trials for biotech companies, including COVID-19 trials. It has specialised expertise in oncology, central nervous system disorders, dermatology, and cardiovascular and rare diseases. IQVIA Biotech has regional headquarters in Singapore and offices in 15 countries across the region.

“I am very excited to bring the IQVIA Biotech Solution to ANZ. This is a game-changer for us to operate with the flexibility and agility needed for the Biotech sector," said Qiao Watkins, senior director, ANZ Biotech Delivery Unit and head of IQVIA Biotech ANZ.

"More and more innovative compounds are being developed by emerging biotech companies, and with this solution we can speed up the drug development process without compromising quality. The past year, COVID-19 has shown us we must find better and faster ways to develop new treatments.”